Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats

Vascular Pharmacology

Volumn 51, Issue 5-6, 2009, Pages 337-343

  Ke, Qingen ^a   Bodyak, Natalya ^a   Rigor, Debra L ^a   Hurst, Nicole W ^b   Chaplin, David J ^b   Kang, Peter M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b OXiGENE Inc   (United States)

Author keywords

Antiangiogenic; Heart; Hypertension; Side effect; Troponin

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; DILTIAZEM; GLYCERYL TRINITRATE; METOPROLOL; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HYPERTENSION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METOPROLOL; NITROGLYCERIN; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STILBENES; TROPONIN I;

EID: 70449109160     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.08.004     Document Type: Article

References (20)

1. Anderson H.L., Yap J.T., Miller M.P., Robbins A., Jones T., and Price P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21 (2003) 2823-2830
2. Chaplin D.J., Horsman M.R., and Siemann D.W. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 7 (2006) 522-528
3. Chaplin D.J., Pettit G.R., Parkins C.S., and Hill S.A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer. Suppl. 27 (1996) S86-88
4. Cooney M.M., Radivoyevitch T., Dowlati A., Overmoyer B., Levitan N., Robertson K., Levine S.L., DeCaro K., Buchter C., Taylor A., Stambler B.S., and Remick S.C. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 10 (2004) 96-100
5. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57 (1997) 1829-1834
6. Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R., Locke R.J., Vojnovic B., and Tozer G.M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21 (2001) 93-102
7. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., Stirling J.J., Sena L., Padhani A.R., and Rustin G.J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21 (2003) 2831-2842
8. Gibbons G.H. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am. J. Cardiol. 79 (1997) 3-8
9. Gould S., Westwood F.R., Curwen J.O., Ashton S.E., Roberts D.W., Lovick S.C., and Ryan A.J. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J. Natl. Cancer Inst. 99 (2007) 1724-1728
10. Grosios K., Holwell S.E., McGown A.T., Pettit G.R., and Bibby M.C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81 (1999) 1318-1327
11. Hamel E., and Lin C.M. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem. Pharmacol. 32 (1983) 3864-3867
12. Malek A.M., Lee I.W., Alper S.L., and Izumo S. Regulation of endothelin-1 gene expression by cell shape and the microfilament network in vascular endothelium. Am. J. Physiol. 273 (1997) C1764-1774
13. Pettit G.R., Xu J.P., Hogan F., Williams M.D., Doubek D.L., Schmidt J.M., Cerny R.L., and Boyd M.R. Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16. J. Nat. Prod. 60 (1997) 752-754
14. Prise V.E., Honess D.J., Stratford M.R., Wilson J., and Tozer G.M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21 (2002) 717-726
15. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., and Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21 (2003) 2815-2822
16. Stevenson J.P., Rosen M., Sun W., Gallagher M., Haller D.G., Vaughn D., Giantonio B., Zimmer R., Petros W.P., Stratford M., Chaplin D., Young S.L., Schnall M., and O Dwyer P.J. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21 (2003) 4428-4438
17. Tarnavski O., McMullen J.R., Schinke M., Nie Q., Kong S., and Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. genomics 16 (2004) 349-360
18. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R., Dennis M.F., and Chaplin D.J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59 (1999) 1626-1634
19. Tron G.C., Pirali T., Sorba G., Pagliai F., Busacca S., and Genazzani A.A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem. 49 (2006) 3033-3044
20. Young S.L., and Chaplin D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs 13 (2004) 1171-1182